Rafferty Asset Management
KRTX

Rafferty Asset Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Rafferty Asset Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-43,693
Closed -$13.8M – 1102
2023
Q4 		$13.8M Sell
43,693
-4,667
-10% -$907K 0.06% 205
2023
Q3 		$8.18M Buy
48,360
+11,883
+33% +$2.23M 0.05% 280
2023
Q2 		$7.91M Sell
36,477
-1,478
-4% -$317K 0.04% 284
2023
Q1 		$6.89M Sell
37,955
-3,097
-8% -$592K 0.05% 297
2022
Q4 		$8.07M Buy
41,052
+13,226
+48% +$2.84M 0.07% 258
2022
Q3 		$6.26M Sell
27,826
-9,732
-26% -$1.97M 0.07% 274
2022
Q2 		$4.75M Sell
37,558
-14,416
-28% -$1.66M 0.04% 284
2022
Q1 		$6.59M Buy
51,974
+11,371
+28% +$1.28M 0.04% 296
2021
Q4 		$5.32M Buy
40,603
+14,433
+55% +$1.87M 0.03% 370
2021
Q3 		$3.2M Buy
26,170
+6,986
+36% +$806K 0.02% 440
2021
Q2 		$2.19M Sell
19,184
-8,710
-31% -$1.02M 0.01% 662
2021
Q1 		$3.35M Buy
27,894
+20,859
+297% +$2.36M 0.02% 419
2020
Q4 		$715K Sell
7,035
-13,284
-65% -$1.23M 0.01% 604
2020
Q3 		$1.57M Buy
20,319
+11,837
+140% +$1.01M 0.02% 485
2020
Q2 		$945K Buy
+8,482
New +$737K 0.01% 565

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Rafferty Asset Management's KRTX Position: Q1 2024 in Review

Rafferty Asset Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 43,693 shares — an estimated $13.8M sold.

Rafferty Asset Management first reported a position in KRTX in Q2 2020 and held it in 15 quarters. The position peaked at $13.8M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Rafferty Asset Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Rafferty Asset Management sold 43,693 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $13.8M.
  • Rafferty Asset Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2020 and held it in 15 quarters.
  • Rafferty Asset Management's Karuna Therapeutics, Inc. Common Stock position peaked at $13.8M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Rafferty Asset Management's 13F filing for Q1 2024, filed 13 May 2024.